 Daré Bioscience, Inc. DARE, a leader in womens health innovation, today reported financial results for the first quarter ended March 31, 2020 and provided a company update. The first quarter was an active one for Daré, beginning with the commercial licensing agreement with Bayer for Ovaprene and continuing with important progress in advancing the development of each of our later-stage product candidates, said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. In addition, we currently believe that we will be able to report topline data for our planned Phase 2b study of Sildenafil Cream, 3.6 in female sexual arousal disorder in 2021 and topline data for our planned pivotal contraceptive study of Ovaprene in 2022. 